FERRISELTZ
LOE ApproachingNDAORALFOR SOLUTION
Approved
Oct 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERRISELTZ is an oral solution approved by the FDA in 1997 for an unknown indication; the generic name and mechanism of action are not disclosed in available data. Given the formulation type and Otsuka sponsorship, it likely addresses a chronic condition requiring oral iron supplementation or similar micronutrient therapy.
LOE Approaching
Product is in late lifecycle phase with moderate competitive pressure (30/100), signaling a contracting brand team focused on margin defense rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FERRISELTZ offers limited career advancement given its LOE-approaching status and zero linked job openings; roles are primarily focused on lifecycle management, cost containment, and regulatory compliance. This assignment is better suited to early-career professionals seeking operational expertise or specialists managing mature portfolios.
Brand ManagerProduct Manager
Worked on FERRISELTZ at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.